High Net Worth Advisory Group’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$534K Hold
6,000
– – 0.11% 150
2026
Q2
$533K Hold
6,000
– – 0.11% 147
2026
Q1
$303K Buy
+6,000
New +$226K 0.07% 194

Other funds holding SYRE

High Net Worth Advisory Group's SYRE Position: Q3 2026 in Review

High Net Worth Advisory Group held its Spyre Therapeutics (SYRE) position steady in Q3 2026 at 6,000 shares worth $534K. The position accounts for 0.11% of the portfolio, ranked #150.

High Net Worth Advisory Group first reported a position in SYRE in Q1 2026 and has held it in 3 quarters since. 285 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • High Net Worth Advisory Group held 6,000 shares of Spyre Therapeutics worth $534K as of Q3 2026.
  • High Net Worth Advisory Group left its Spyre Therapeutics share count unchanged in Q3 2026.
  • Spyre Therapeutics made up 0.11% of High Net Worth Advisory Group's portfolio in Q3 2026, its #150 holding.
  • High Net Worth Advisory Group first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 285 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on High Net Worth Advisory Group's 13F filing for Q3 2026, filed 26 Oct 2026.